Innovative Trials Limited - Accounts to registrar (filleted) - small 18.2

Innovative Trials Limited - Accounts to registrar (filleted) - small 18.2


IRIS Accounts Production v19.3.2.199 07181523 Board of Directors Board of Directors 1.6.18 31.5.19 31.5.19 false true false false false true false 553 137 1415567 162000 770416 162416 644598 553 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure071815232018-05-31071815232019-05-31071815232018-06-012019-05-31071815232017-05-31071815232017-06-012018-05-31071815232018-05-3107181523ns15:EnglandWales2018-06-012019-05-3107181523ns14:PoundSterling2018-06-012019-05-3107181523ns10:Director12018-06-012019-05-3107181523ns10:Director22018-06-012019-05-3107181523ns10:PrivateLimitedCompanyLtd2018-06-012019-05-3107181523ns10:SmallEntities2018-06-012019-05-3107181523ns10:AuditExempt-NoAccountantsReport2018-06-012019-05-3107181523ns10:SmallCompaniesRegimeForDirectorsReport2018-06-012019-05-3107181523ns10:SmallCompaniesRegimeForAccounts2018-06-012019-05-3107181523ns10:FullAccounts2018-06-012019-05-310718152312018-06-012019-05-3107181523ns10:Director2422018-05-3107181523ns10:Director2422017-05-3107181523ns10:Director2422018-06-012019-05-3107181523ns10:Director2422017-06-012018-05-3107181523ns10:Director2422019-05-3107181523ns10:Director2422018-05-3107181523ns10:RegisteredOffice2018-06-012019-05-3107181523ns5:CurrentFinancialInstruments2019-05-3107181523ns5:CurrentFinancialInstruments2018-05-3107181523ns5:ShareCapital2019-05-3107181523ns5:ShareCapital2018-05-3107181523ns5:SharePremium2019-05-3107181523ns5:SharePremium2018-05-3107181523ns5:RetainedEarningsAccumulatedLosses2019-05-3107181523ns5:RetainedEarningsAccumulatedLosses2018-05-3107181523ns5:IntangibleAssetsOtherThanGoodwill2018-06-012019-05-3107181523ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2018-06-012019-05-3107181523ns5:PlantMachinery2018-06-012019-05-3107181523ns5:FurnitureFittings2018-06-012019-05-3107181523ns5:ComputerEquipment2018-06-012019-05-3107181523ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2018-05-3107181523ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2019-05-3107181523ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2018-05-3107181523ns5:LeaseholdImprovements2018-05-3107181523ns5:PlantMachinery2018-05-3107181523ns5:FurnitureFittings2018-05-3107181523ns5:ComputerEquipment2018-05-3107181523ns5:LeaseholdImprovements2018-06-012019-05-3107181523ns5:LeaseholdImprovements2019-05-3107181523ns5:PlantMachinery2019-05-3107181523ns5:FurnitureFittings2019-05-3107181523ns5:ComputerEquipment2019-05-3107181523ns5:LeaseholdImprovements2018-05-3107181523ns5:PlantMachinery2018-05-3107181523ns5:FurnitureFittings2018-05-3107181523ns5:ComputerEquipment2018-05-3107181523ns5:CurrentFinancialInstrumentsns5:WithinOneYear2019-05-3107181523ns5:CurrentFinancialInstrumentsns5:WithinOneYear2018-05-3107181523ns5:WithinOneYear2019-05-3107181523ns5:WithinOneYear2018-05-3107181523ns5:BetweenOneFiveYears2019-05-3107181523ns5:BetweenOneFiveYears2018-05-3107181523ns5:AllPeriods2019-05-3107181523ns5:AllPeriods2018-05-3107181523ns10:Director112018-05-3107181523ns10:Director112017-05-3107181523ns10:Director112018-06-012019-05-3107181523ns10:Director112017-06-012018-05-3107181523ns10:Director112019-05-3107181523ns10:Director112018-05-31


REGISTERED NUMBER: 07181523 (England and Wales)















Report of the Directors and

Unaudited Financial Statements

for the Year Ended 31 May 2019

for

INNOVATIVE TRIALS LIMITED

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Contents of the Financial Statements
for the year ended 31 May 2019










Page

Company Information 1

Report of the Directors 2

Balance Sheet 3

Notes to the Financial Statements 5


INNOVATIVE TRIALS LIMITED

Company Information
for the year ended 31 May 2019







Directors: Ms K Shaw
Mr D Watkins





Registered office: 305 Regents Park Road
Finchley
London
N3 1DP





Registered number: 07181523 (England and Wales)





Accountants: Haines Watts
Chartered Accountants
305 Regents Park Road
Finchley
London
N3 1DP

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Report of the Directors
for the year ended 31 May 2019


The directors present their report with the financial statements of the company for the year ended 31 May 2019.

Principal activity
The principal activity of the company in the year under review was that of the provision of patient recruitment services
to the pharmaceutical industry.

Review of business
2018 - 2019 was Innovative Trials 9th year in business and saw our company grow significantly in terms of turnover,
profit and staff numbers. We have also brought on new functions which has provided depth to the company.

Our new office space has provided our team with enhanced facilities and it is great to see them being used. We are
already reaching capacity though and so will be moving to larger premises again within the next financial year.

The Executive team continues to develop and provide direction and leadership to the growing organisation. The
Executive team will continue to execute on our company goals to bring with it continued growth.

We continue to develop and enhance our patient recruitment services and we are delighted that they are bringing with
them success for our clients and enabling them to meet their patient recruitment goals on a regular basis. Patient
recruitment remains a rewarding and worthwhile area to work in and we continue to enjoy what we do.

Our 2019 - 2020 targets are set at a level to be challenging, but with the team we have in place, we are confident are
achievable.

Directors
The directors shown below have held office during the whole of the period from 1 June 2018 to the date of this report.

Ms K Shaw
Mr D Watkins

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to
small companies.

On behalf of the board:





Ms K Shaw - Director


12 December 2019

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Balance Sheet
31 May 2019

2019 2018
Notes £ £ £ £
Fixed assets
Intangible assets 4 2,400 4,800
Tangible assets 5 93,467 90,542
95,867 95,342

Current assets
Debtors 6 2,615,639 1,033,448
Cash at bank and in hand 1,822,168 2,414,291
4,437,807 3,447,739
Creditors
Amounts falling due within one year 7 802,004 532,434
Net current assets 3,635,803 2,915,305
Total assets less current liabilities 3,731,670 3,010,647

Provisions for liabilities 8,812 8,256
Net assets 3,722,858 3,002,391

Capital and reserves
Called up share capital 9 120 100
Share premium 488,380 -
Retained earnings 3,234,358 3,002,291
3,722,858 3,002,391

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2019 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies
Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end
of each financial year and of its profit or loss for each financial year in accordance with the requirements of
Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to
financial statements, so far as applicable to the company.

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Balance Sheet - continued
31 May 2019


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors on 12 December 2019 and were signed on its behalf
by:




Ms K Shaw - Director



Mr D Watkins - Director


INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Notes to the Financial Statements
for the year ended 31 May 2019


1. Statutory information

Innovative Trials Limited is a private company, limited by shares , registered in England and Wales. The
company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Key source of estimation, uncertainty and judgement
The preparation of financial statements in conformity with generally accepted accounting practice requires
management to make estimates and judgement that affect the reported amounts of assets and liabilities as well
as the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of
revenues and expenses during the reporting period.

There is estimation uncertainty in calculating depreciation. A full line by line review of fixed assets is carried
out by management regularly. Whilst every attempt is made to ensure that the depreciation policy is as accurate
as possible, there remains a risk that the policy does not match the useful life of the assets.

There is estimation uncertainty in calculating deferred tax. A full line by line review of deferred tax is carried
out by management regularly. Whilst every attempt is made to ensure that the deferred tax is accurate as
possible, there remains a risk that the provisions do not match the actual tax liability when asset is disposed
off.

There is estimation uncertainty in calculating bad debt provisions. A full line by line review of trade debtors is
carried out at the end of each month. Whilst every attempt is made to ensure that the bad debt provisions are as
accurate as possible, there remains a risk that the provisions do not match the level of debts which ultimately
prove to be uncollectable.

There is estimation uncertainty in calculating amortisation of intangible assets. A full line by line review of
intangible assets is carried out by management regularly. Whilst every attempt is made to ensure that the
amortisation policy is as accurate as possible, there remains a risk that the policy does not match the useful life
of the intangible assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates,
value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost
less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of three years.

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Notes to the Financial Statements - continued
for the year ended 31 May 2019


2. Accounting policies - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 25% on reducing balance
Computer equipment - 25% on reducing balance

Financial instruments
Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party
to the contractual provisions of the instrument.

Trade and other debtors and creditors are classified as basic financial instruments and measured at initial
recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the
effective interest rate method. A provision is established when there is objective evidence that the company will
not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank
and bank overdrafts which are integral part of the company’s cash management.

Financial liabilities and equity instruments issued by the company are classified in accordance with the
substance of the contractual arrangements entered into and the definitions of a financial liability and an equity
instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company
after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds
received, net of direct issue costs.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account,
except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or
substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the
balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different
from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and
laws that have been enacted or substantively enacted by the year end and that are expected to apply to the
reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they
will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension
scheme are charged to profit or loss in the period to which they relate.

3. Employees and directors

The average number of employees during the year was 26 (2018 - 19 ) .

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Notes to the Financial Statements - continued
for the year ended 31 May 2019


4. Intangible fixed assets
Development
costs
£
Cost
At 1 June 2018
and 31 May 2019 7,200
Amortisation
At 1 June 2018 2,400
Amortisation for year 2,400
At 31 May 2019 4,800
Net book value
At 31 May 2019 2,400
At 31 May 2018 4,800

5. Tangible fixed assets
Fixtures
Improvements Plant and and Computer
to property machinery fittings equipment Totals
£ £ £ £ £
Cost
At 1 June 2018 47,088 30,129 35,252 8,022 120,491
Additions - - 900 17,485 18,385
At 31 May 2019 47,088 30,129 36,152 25,507 138,876
Depreciation
At 1 June 2018 - 19,130 8,813 2,006 29,949
Charge for year - 2,750 6,835 5,875 15,460
At 31 May 2019 - 21,880 15,648 7,881 45,409
Net book value
At 31 May 2019 47,088 8,249 20,504 17,626 93,467
At 31 May 2018 47,088 10,999 26,439 6,016 90,542

6. Debtors: amounts falling due within one year
2019 2018
£ £
Trade debtors 1,847,231 935,752
Other debtors 768,408 97,696
2,615,639 1,033,448

INNOVATIVE TRIALS LIMITED (REGISTERED NUMBER: 07181523)

Notes to the Financial Statements - continued
for the year ended 31 May 2019


7. Creditors: amounts falling due within one year
2019 2018
£ £
Trade creditors 265,544 181,074
Taxation and social security 383,011 348,307
Other creditors 153,449 3,053
802,004 532,434

8. Leasing agreements

Minimum lease payments under non-cancellable operating leases fall due as follows:
2019 2018
£ £
Within one year 14,690 24,192
Between one and five years 22,500 50,500
37,190 74,692

9. Called up share capital

Allotted, issued and fully paid:

Number: Class: Nominal 2019 2018
value: £    £   
100 Ordinary £1 - 100
50 Ordinary A £1 50 -
50 Ordinary B £1 50 -
20 Ordinary C £1 20 -
120 100

20 Ordinary C shares of £1 each were allotted as fully paid at a premium of £24,419 per share during the year.

10. Directors' advances, credits and guarantees

The following advances and credits to directors subsisted during the years ended 31 May 2019 and
31 May 2018:

2019 2018
£ £
Ms K Shaw and Mr D Watkins
Balance outstanding at start of year (553 ) (137 )
Amounts advanced 1,415,567 162,000
Amounts repaid (770,416 ) (162,416 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 644,598 (553 )

The directors loan from the company was repaid within nine months of the company year end date.